RxDoctor Payments DataLook up a doctor →

Tarek Ajam, MD

Clinical Cardiac Electrophysiology · Hobart, INNPI 1588059356

Payments from drug & device makers

$52,650in general payments, 2019–2025

Across 418 payments — averaging $125.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$21K
  • Boston Scientific$11K
  • Abbott$10K
  • Biotronik Inc.$2K
  • Biosense Webster, Inc.$2K
  • Medical Device Business Services, Inc.$1K
  • plus $5K from 35 others

What the payments were for

  • Consulting fees$1,1252%
  • Grants$19,58337%
  • Travel & lodging$15,25329%
  • Food & beverage$15,26129%
  • Education$1,4283%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,650 in reported general payments places this provider in the 70th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

See all clinical cardiac electrophysiology providers in Indiana

Medicare billing

Part B allowed, 2024
$174,036
Medicare patients
1,142
Services billed
2,487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban98$72,038
MounjaroTirzepatide49$58,270
XareltoRivaroxaban12$8,958
Colchicine44$1,956
Metoprolol Succinate82$845
Bisoprolol Fumarate11$413
Pantoprazole Sodium44$236
Metoprolol Tartrate57$235
Amiodarone Hcl24$235
Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide12$144
Carvedilol17$122
Furosemide18$30
Losartan Potassium12$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$134$72,03898 claims
Lilly USA, LLCMounjaro$56$58,27049 claims
Johnson & JohnsonXarelto$182$8,95812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 72 clinical cardiac electrophysiology providers in Indiana.

Other clinical cardiac electrophysiology in Hobart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →